BACKGROUND AND PURPOSE: Few studies have addressed outcomes among patients ≥80 years treated with acute stroke therapy. In this study, we outline in-hospital outcomes in (1) patients ≥80 years compared with their younger counterparts; and (2) those over >80 years receiving intra-arterial therapy (IAT) compared with those treated with intravenous recombinant tissue-type plasminogen activator (IV rtPA). METHODS: Stroke centers within the Specialized Program of Translational Research in Acute Stroke (SPOTRIAS) prospectively collected data on all patients treated with IV rtPA or IAT from January 1, 2005, to December 31, 2010. IAT was defined as receiving any endovascular therapy; IAT was further divided into bridging therapy when the patient received both IAT and IV rtPA and endovascular therapy alone. In-hospital mortality was compared in (1) all patients aged ≥80 years versus younger counterparts; and (2) IAT, bridging therapy, and endovascular therapy alone versus IV rtPA only among those age ≥80 years using multivariable logistic regression. An age-stratified analysis was also performed. RESULTS: A total of 3768 patients were included in the study; 3378 were treated with IV rtPA alone and 808 with IAT (383 with endovascular therapy alone and 425 with bridging therapy). Patients ≥80 years (n=1182) had a higher risk of in-hospital mortality compared with younger counterparts regardless of treatment modality (OR, 2.13; 95% CI, 1.60-2.84). When limited to those aged ≥80 years, IAT (OR, 0.95; 95% CI, 0.60-1.49), bridging therapy (OR, 0.82; 95% CI, 0.47-1.45), or endovascular therapy alone (OR, 1.15; 95% CI, 0.64-2.08) versus IV rtPA were not associated with increased in-hospital mortality. CONCLUSIONS: IAT does not appear to increase the risk of in-hospital mortality among those aged >80 years compared with IV thrombolysis alone.
BACKGROUND AND PURPOSE: Few studies have addressed outcomes among patients ≥80 years treated with acute stroke therapy. In this study, we outline in-hospital outcomes in (1) patients ≥80 years compared with their younger counterparts; and (2) those over >80 years receiving intra-arterial therapy (IAT) compared with those treated with intravenous recombinant tissue-type plasminogen activator (IV rtPA). METHODS:Stroke centers within the Specialized Program of Translational Research in Acute Stroke (SPOTRIAS) prospectively collected data on all patients treated with IV rtPA or IAT from January 1, 2005, to December 31, 2010. IAT was defined as receiving any endovascular therapy; IAT was further divided into bridging therapy when the patient received both IAT and IV rtPA and endovascular therapy alone. In-hospital mortality was compared in (1) all patients aged ≥80 years versus younger counterparts; and (2) IAT, bridging therapy, and endovascular therapy alone versus IV rtPA only among those age ≥80 years using multivariable logistic regression. An age-stratified analysis was also performed. RESULTS: A total of 3768 patients were included in the study; 3378 were treated with IV rtPA alone and 808 with IAT (383 with endovascular therapy alone and 425 with bridging therapy). Patients ≥80 years (n=1182) had a higher risk of in-hospital mortality compared with younger counterparts regardless of treatment modality (OR, 2.13; 95% CI, 1.60-2.84). When limited to those aged ≥80 years, IAT (OR, 0.95; 95% CI, 0.60-1.49), bridging therapy (OR, 0.82; 95% CI, 0.47-1.45), or endovascular therapy alone (OR, 1.15; 95% CI, 0.64-2.08) versus IV rtPA were not associated with increased in-hospital mortality. CONCLUSIONS: IAT does not appear to increase the risk of in-hospital mortality among those aged >80 years compared with IV thrombolysis alone.
Authors: Chin-I Chen; Yasuyuki Iguchi; James C Grotta; Zsolt Garami; Ken Uchino; Hashem Shaltoni; Andrei V Alexandrov Journal: Eur Neurol Date: 2005-10-18 Impact factor: 1.710
Authors: S T Engelter; M Reichhart; L Sekoranja; D Georgiadis; A Baumann; B Weder; F Müller; R Lüthy; M Arnold; P Michel; H P Mattle; B Tettenborn; H J Hungerbühler; R W Baumgartner; R Sztajzel; J Bogousslavsky; P A Lyrer Journal: Neurology Date: 2005-10-12 Impact factor: 9.910
Authors: M S Mouradian; A Senthilselvan; G Jickling; J A McCombe; D J Emery; N Dean; A Shuaib Journal: J Neurol Neurosurg Psychiatry Date: 2005-09 Impact factor: 10.154
Authors: Jessica E Simon; David L Sandler; J H Warwick Pexman; Michael D Hill; Alastair M Buchan Journal: Age Ageing Date: 2004-03 Impact factor: 10.668
Authors: Karen C Albright; Sean I Savitz; Rema Raman; Sheryl Martin-Schild; Joseph Broderick; Karin Ernstrom; Andria Ford; Rakesh Khatri; Dawn Kleindorfer; David Liebeskind; Randolph Marshall; José G Merino; Dawn M Meyer; Natalia Rost; Brett C Meyer Journal: Cerebrovasc Dis Date: 2012-12-01 Impact factor: 2.762
Authors: Amrou Sarraj; Karen Albright; Andrew D Barreto; Amelia K Boehme; Clark W Sitton; Jeanie Choi; Steven L Lutzker; Chung-Huan J Sun; Wafi Bibars; Claude B Nguyen; Osman Mir; Farhaan Vahidy; Tzu-Ching Wu; George A Lopez; Nicole R Gonzales; Randall Edgell; Sheryl Martin-Schild; Hen Hallevi; Peng Roc Chen; Mark Dannenbaum; Jeffrey L Saver; David S Liebeskind; Raul G Nogueira; Rishi Gupta; James C Grotta; Sean I Savitz Journal: Stroke Date: 2013-08-08 Impact factor: 7.914
Authors: Raluca Elena Sandu; Ana Maria Buga; Adriana Uzoni; Eugen Bogdan Petcu; Aurel Popa-Wagner Journal: Neural Regen Res Date: 2015-09 Impact factor: 5.135
Authors: Ronil V Chandra; Thabele M Leslie-Mazwi; Brijesh P Mehta; Albert J Yoo; Claus Z Simonsen Journal: Front Neurol Date: 2014-04-29 Impact factor: 4.003
Authors: Joshua Z Willey; Yeseon Park Moon; Emily Kahn; Carlos J Rodriguez; Tatjana Rundek; Ken Cheung; Ralph L Sacco; Mitchell S V Elkind Journal: J Am Heart Assoc Date: 2014-09-16 Impact factor: 5.501